{"content":"<li class=\"n-box-item date-title\" data-end=\"1538798399\" data-start=\"1538712000\" data-txt=\"Monday, December 23, 2019\">Friday, October  5, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3395598\" data-ts=\"1538775797\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WSM\" target=\"_blank\">WSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395598-after-hours-gainers-losers-10-05-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (10/05/2018)</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/WSM' title='Williams-Sonoma Inc.'>WSM</a> <font color='green'>+14.9%</font>. <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='green'>+9.5%</font>. <a href='https://seekingalpha.com/symbol/KALA' title='Kala Pharmaceuticals'>KALA</a> <font color='green'>+8.6%</font>. <a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings'>SENS</a> <font color='green'>+4.9%</font>. <a href='https://seekingalpha.com/symbol/NTRA' title='Natera'>NTRA</a> <font color='green'>+4.9%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='red'>-4.6%</font>. <a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a> <font color='red'>-4.4%</font>. <a href='https://seekingalpha.com/symbol/NVTA' title='Invitae'>NVTA</a> <font color='red'>-3.6%</font>. <a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color='red'>-3.3%</font>. <a href='https://seekingalpha.com/symbol/INGN' title='Inogen, Inc'>INGN</a> <font color='red'>-2.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395598\" data-linked=\"After Hours Gainers / Losers (10/05/2018)\" data-tweet=\"$WSM $WSM $ALT - After Hours Gainers / Losers (10/05/2018) https://seekingalpha.com/news/3395598-after-hours-gainers-losers-10-05-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3395598-after-hours-gainers-losers-10-05-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395595\" data-ts=\"1538774613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KALA\" target=\"_blank\">KALA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395595-kala-pharmaplus-8_7-shareholder-discloses-20m-purchase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kala Pharma +8.7% as shareholder discloses $20M purchase</a></h4><ul>   <li>Kala Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KALA' title='Kala Pharmaceuticals'>KALA</a>) is <font color='green'>up 8.7%</font> in after-hours trading following a filing from shareholder RA Capital Management disclosing a <a href=\"https://seekingalpha.com/filing/4194854\" target=\"_blank\">2.42M-share purchase</a>.</li>    <li>The firm (a 10% holder) bought 2,424,242 shares on Wednesday at an average price of $8.25, for just under $20M total.</li>    <li>That brings beneficial ownership to 4,537,478 shares.</li>    <li>Shares had closed <font color='red'>down 2.2%</font> to $7.73 today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395595\" data-linked=\"Kala Pharma +8.7% as shareholder discloses $20M purchase\" data-tweet=\"$KALA - Kala Pharma +8.7% as shareholder discloses $20M purchase https://seekingalpha.com/news/3395595-kala-pharmaplus-8_7-shareholder-discloses-20m-purchase?source=tweet\" data-url=\"https://seekingalpha.com/news/3395595-kala-pharmaplus-8_7-shareholder-discloses-20m-purchase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395570\" data-ts=\"1538769682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIVI\" target=\"_blank\">CIVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395570-civitas-to-explore-strategic-alternatives-shares-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Civitas to explore strategic alternatives; shares up 10%</a></h4><ul><li>Reuters <a href=\"https://www.reuters.com/article/us-apple-greenlight-stake/despondent-musks-tesla-resembles-lehman-greenlights-einhorn-says-idUSKCN1MF27C\" target=\"_blank\">reports </a>that home health services provider Civitas Solutions (<a href='https://seekingalpha.com/symbol/CIVI' title='Civitas Solutions'>CIVI</a> <font color='green'>+10%</font>) is exploring strategic alternatives, including a possible sale.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395570\" data-linked=\"Civitas to explore strategic alternatives; shares up 10%\" data-tweet=\"$CIVI - Civitas to explore strategic alternatives; shares up 10% https://seekingalpha.com/news/3395570-civitas-to-explore-strategic-alternatives-shares-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3395570-civitas-to-explore-strategic-alternatives-shares-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395568\" data-ts=\"1538769275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDR\" target=\"_blank\">CLDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395568-software-industrys-week-topped-cloudera-hortonworks-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Software industry&#39;s week topped by Cloudera-Hortonworks merger</a></h4><ul><li>        The software and services industry is heading towards the end of the week&nbsp;<font color='red'>down 2.1%</font>&nbsp;in the month compared to the&nbsp;<font color='red'>1.8% decline&nbsp;</font>for IT. The merger of Cloudera (NYSE:<a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a>) and Hortonworks (NASDAQ:<a href='https://seekingalpha.com/symbol/HDP' title='Hortonworks'>HDP</a>) was one of the biggest stories with the stocks&nbsp;<font color='green'>up 8.4%</font>&nbsp;and&nbsp;<font color='green'>8.7%</font>&nbsp;for the week, respectively.</li><li>               Other industry movers (% for the week):&nbsp;</li><li>               Upland Software (NASDAQ:<a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software'>UPLD</a>)&nbsp;<font color='green'>up 12.1%</font>&nbsp;after an acquisition-related FY guidance boost.&nbsp;</li><li>               Progress Software (NASDAQ:<a href='https://seekingalpha.com/symbol/PRGS' title='Progress Software Corporation'>PRGS</a>)&nbsp;<font color='red'>down 17.7%</font>&nbsp;after reporting a mixed Q3 with downside guides on September 27.&nbsp;</li><li>               ShotSpotter (NASDAQ:<a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a>)&nbsp;<font color='red'>down 15.5%</font>&nbsp;on today&rsquo;s Imperial downgrade and Wednesday&rsquo;s acquisition of predictive policing startup HunchLab.&nbsp;</li><li>               Alarm.com (NASDAQ:<a href='https://seekingalpha.com/symbol/ALRM' title='Alarm.com'>ALRM</a>)&nbsp;<font color='red'>down 3.5%</font>&nbsp;for the week and&nbsp;<font color='red'>6% today&nbsp;</font>after being named to Hedgeye&rsquo;s best short list.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393581-progress-software-minus-13-percent-mixed-q3-downside-q4-fy-guides\" target=\"_blank\">Progress Software -13% on mixed Q3, downside Q4 and FY guides</a> (Sept. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3394792-upland-software-plus-8_5-percent-acquisition-related-fy-guide-boost\" target=\"_blank\">Upland Software +8.5% on acquisition-related FY guide boost</a> (Oct. 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3394930-cloudera-soars-hortonworks-merger\" target=\"_blank\">Cloudera soars on Hortonworks merger</a> (Oct. 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395434-hedgeye-names-alarm-com-best-idea-short-list\" target=\"_blank\">Hedgeye names Alarm.com to Best Idea Short List</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395568\" data-linked=\"Software industry&#39;s week topped by Cloudera-Hortonworks merger\" data-tweet=\"$CLDR $CLDR $HDP - Software industry&#39;s week topped by Cloudera-Hortonworks merger https://seekingalpha.com/news/3395568-software-industrys-week-topped-cloudera-hortonworks-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3395568-software-industrys-week-topped-cloudera-hortonworks-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395567\" data-ts=\"1538768878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RWEOY\" target=\"_blank\">RWEOY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395567-rweminus-8-on-court-ruling-effectively-blocking-expansion-of-key-mine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RWE -8% on court ruling effectively blocking expansion of key mine</a></h4><ul>     <li>Shares in German utility RWE&nbsp;(<a href='https://seekingalpha.com/symbol/RWEOY' title='RWE AG ADR'>OTCPK:RWEOY</a> <font color='red'>-8.6%</font>) tumble more than 8% following a surprise administrative court ruling that effectively <a href=\"https://www.ft.com/content/116c2cd6-c8c2-11e8-ba8f-ee390057b8c9\" target=\"_blank\">blocks the expansion of a critical lignite mine</a> operated by the company.</li>     <li>RWE says the ruling had &ldquo;far-reaching ramifications&rdquo; for its business, and could cost the group a &ldquo;low three-digit million euro amount.\"</li>     <li>The ruling prohibits RWE from clearing the Hambach forest, which has been the focal point of environmental protests for years and sits next to one of the company&rsquo;s lignite mines.</li>     <li>The court said clearance should not go ahead until a separate legal case dealing with the planned destruction of the forest has been decided and that RWE had not been able to show that a delay posed a risk to energy supply.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395567\" data-linked=\"RWE -8% on court ruling effectively blocking expansion of key mine\" data-tweet=\"$RWEOY - RWE -8% on court ruling effectively blocking expansion of key mine https://seekingalpha.com/news/3395567-rweminus-8-on-court-ruling-effectively-blocking-expansion-of-key-mine?source=tweet\" data-url=\"https://seekingalpha.com/news/3395567-rweminus-8-on-court-ruling-effectively-blocking-expansion-of-key-mine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395566\" data-ts=\"1538768795\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395566-ionis-and-akcea-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ionis and Akcea shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='green'>+2.7%</font>) and Akcea Therapeutics (<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+5.2%</font>) pending the release of news, most certainly related to the FDA decision on inotersen for hATTR.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395566\" data-linked=\"Ionis and Akcea shares halted pending news\" data-tweet=\"$IONS $IONS $AKCA - Ionis and Akcea shares halted pending news https://seekingalpha.com/news/3395566-ionis-and-akcea-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3395566-ionis-and-akcea-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395564\" data-ts=\"1538768534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALT\" target=\"_blank\">ALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395564-altimmunes-flu-vaccine-nasal-spray-shows-strong-immune-effect-in-mid-stage-study-shares-up-38\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altimmune&#39;s flu vaccine nasal spray shows strong immune effect in mid-stage study; shares up 38%</a></h4><ul><li>Thinly traded nano cap Altimmune (<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='green'>+38.3%</font>) is up on a healthy 31x surge in volume in reaction to the <a href=\"https://idsa.confex.com/idsa/2018/webprogram/Paper72215.html\" target=\"_blank\">results </a>from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03232567?term=altimmune&amp;rank=2\" target=\"_blank\">Phase 2 clinical trial </a>evaluating single ascending doses of its NasoVAX nasal spray flu vaccine. The data were presented at IDWeek in San Francisco.</li><li>Participants receiving the two highest doses (10<sup>10</sup>viral particles and 10<sup>11</sup>viral particles) achieved 100% seroprotection at day 29. It elicited a six-fold higher cellular immune response than Sanofi's (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='red'>-0.9%</font>) <a href=\"http://www.fluzone.com/interstitial.cfm\" target=\"_blank\">Fluzone </a>injectable vaccine.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395564\" data-linked=\"Altimmune&#39;s flu vaccine nasal spray shows strong immune effect in mid-stage study; shares up 38%\" data-tweet=\"$ALT $ALT $SNY - Altimmune&#39;s flu vaccine nasal spray shows strong immune effect in mid-stage study; shares up 38% https://seekingalpha.com/news/3395564-altimmunes-flu-vaccine-nasal-spray-shows-strong-immune-effect-in-mid-stage-study-shares-up-38?source=tweet\" data-url=\"https://seekingalpha.com/news/3395564-altimmunes-flu-vaccine-nasal-spray-shows-strong-immune-effect-in-mid-stage-study-shares-up-38\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395563\" data-ts=\"1538767851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDS\" target=\"_blank\">PDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395563-ensign-energy-sweeten-bid-for-trinidad-ray-jay-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ensign Energy could sweeten bid for Trinidad, Ray Jay analyst says</a></h4><ul>     <li>Precision Drilling (<a href='https://seekingalpha.com/symbol/PDS' title='Precision Drilling Corporation'>PDS</a> <font color='red'>-2.8%</font>) has emerged as a white knight for Trinidad Drilling (<a href='https://seekingalpha.com/symbol/TDGCF' title='Trinidad Drilling Ltd.'>OTCPK:TDGCF</a> <font color='green'>+4.1%</font>) with its <a href=\"https://seekingalpha.com/news/3395378-precision-drilling-buy-trinidad-drilling-1b-deal\" target=\"_blank\">$1B takeover offer</a>, but analysts think Ensign Energy (<a href='https://seekingalpha.com/symbol/ESVIF' title='Ensign Energy Services Inc.'>OTCPK:ESVIF</a> <font color='red'>-8.4%</font>) <a href=\"https://business.financialpost.com/commodities/energy/precision-drilling-emerges-as-white-knight-for-trinidad-but-ensign-may-still-sweeten-bid\" target=\"_blank\">could sweeten its previous $947M offer</a>.</li>     <li>&ldquo;It&rsquo;s impossible to guess [Ensign&rsquo;s] next move with any degree of certainty. It may simply choose to walk away from [Trinidad] though we wouldn&rsquo;t consider that to be its best option - either financially or strategically,&rdquo; Raymond James analyst Andrew Bradford writes.</li>     <li>Bradford says Ensign could afford to increase its cash offer for Trinidad, offer a nominal number of its own shares and pay the $20M break fee Trinidad would have to pay if the PDS deal fails to close.</li>     <li>&ldquo;We continue to believe consolidation is needed in the Canadian energy services sector and expect that Precision and Ensign could potentially increase their bids for Trinidad,&rdquo; says Canaccord Genuity analyst John Bereznicki.</li><li>Perhaps noteworthy, Ensign made an offer in 2002 for Australian Oil &amp; Gas  Corp. and PDS swooped in with a higher bid two months later.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395563\" data-linked=\"Ensign Energy could sweeten bid for Trinidad, Ray Jay analyst says\" data-tweet=\"$PDS $PDS $TDGCF - Ensign Energy could sweeten bid for Trinidad, Ray Jay analyst says https://seekingalpha.com/news/3395563-ensign-energy-sweeten-bid-for-trinidad-ray-jay-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3395563-ensign-energy-sweeten-bid-for-trinidad-ray-jay-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395561\" data-ts=\"1538766464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395561-einhorn-like-lehman-deception-to-catch-up-to-tesla\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Einhorn: &#39;Like Lehman... deception about to catch up to Tesla&#39;</a></h4><ul>     <li>Hedge fund manager David Einhorn slams Tesla (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='red'>-7%</font>) and Elon Musk, saying the company&rsquo;s problems <a href=\"https://www.reuters.com/article/us-apple-greenlight-stake/greenlight-capitals-david-einhorn-likens-tesla-to-lehman-brothers-idUSKCN1MF27C\" target=\"_blank\">resemble those of Lehman Brothers</a> before its collapse.</li>     <li>&ldquo;Like Lehman, we think the deception is about to catch up to TSLA,&rdquo; Einhorn's Greenlight Capital, which has been selling TSLA shares short, says in its latest quarterly letter. \"Elon Musk&rsquo;s erratic behavior suggests that he sees it the same way.\"</li>     <li>&ldquo;Lehman threatened short sellers, refused to raise capital (it even bought back stock), and management publicly suggested it would go private&rdquo; in the months leading up to the bank&rsquo;s collapse, Greenlight says.</li><li><a href=\"https://seekingalpha.com/news/3395530-einhorn-blows-numerous-positions\" target=\"_blank\">Earlier</a>: Einhorn blows out of numerous positions (Oct. 5)</li><li><a href=\"https://seekingalpha.com/news/3395533-tesla-follows-musk-rabbit-hole\" target=\"_blank\">Earlier</a>: Tesla follows Musk down the rabbit hole (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395561\" data-linked=\"Einhorn: &#39;Like Lehman... deception about to catch up to Tesla&#39;\" data-tweet=\"$TSLA - Einhorn: &#39;Like Lehman. deception about to catch up to Tesla&#39; https://seekingalpha.com/news/3395561-einhorn-like-lehman-deception-to-catch-up-to-tesla?source=tweet\" data-url=\"https://seekingalpha.com/news/3395561-einhorn-like-lehman-deception-to-catch-up-to-tesla\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>349&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395559\" data-ts=\"1538766231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGH\" target=\"_blank\">SGH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395559-technology-top-5-gainers-losers-of-3_03-pm-10-05-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3.03 PM (10/05/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/IMI' title='Intermolecular, Inc.'>IMI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='green'>+6%</font>.</li><li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/IPGP' title='IPG Photonics Corporation'>IPGP</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RESN' title='Resonant'>RESN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CGNX' title='Cognex Corporation'>CGNX</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395559\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3.03 PM (10/05/2018)\" data-tweet=\"$SGH $SGH $AWSM - Technology - Top 5 Gainers / Losers as of 3.03 PM (10/05/2018) https://seekingalpha.com/news/3395559-technology-top-5-gainers-losers-of-3_03-pm-10-05-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3395559-technology-top-5-gainers-losers-of-3_03-pm-10-05-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395556\" data-ts=\"1538765581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMN\" target=\"_blank\">EMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395556-eastman-chemicalminus-5-j-p-morgan-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eastman Chemical -5% as J.P. Morgan downgrades</a></h4><ul>     <li>Eastman Chemical (<a href='https://seekingalpha.com/symbol/EMN' title='Eastman Chemical Co.'>EMN</a> <font color='red'>-5.5%</font>) plunges after J.P. Morgan <a href=\"https://thefly.com/thestreet/realmoney/index.php/EMNid2800188/EMN-JPMorgan-downgrades-Eastman-to-Neutral-on-rising-raw-material-costs\" target=\"_blank\">downgrades</a> shares to Neutral from Overweight with a $105 price target, cut from $120, as analyst Jeffrey Zekauskas believes raw material trends likely will pressure the company's year-ahead results.</li>     <li>EMN will begin to face raw material challenges because of rising costs for propane, para-xylene and ethane costs, Zekauskas says, also believing that consensus estimates for EMN's 2019 EBITDA and earnings growth are high.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395556\" data-linked=\"Eastman Chemical -5% as J.P. Morgan downgrades\" data-tweet=\"$EMN - Eastman Chemical -5% as J.P. Morgan downgrades https://seekingalpha.com/news/3395556-eastman-chemicalminus-5-j-p-morgan-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3395556-eastman-chemicalminus-5-j-p-morgan-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395554\" data-ts=\"1538763473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395554-market-likes-ge-ceo-culps-stock-heavy-pay-package-rbc-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Market likes GE CEO Culp&#39;s stock-heavy pay package, RBC analyst says</a></h4><ul>     <li>Shares of General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='green'>+4.4%</font>) are on track for their <a href=\"https://www.marketwatch.com/story/ge-stock-rockets-toward-best-week-since-march-2009-2018-10-05\" target=\"_blank\">biggest weekly gain since March 2009</a> at the nadir of the financial crisis, after surging 17% this week following the surprise leadership change.</li>     <li>RBC&nbsp;Capital analyst Deane Dray, who <a href=\"https://seekingalpha.com/news/3394358-ge-plus-3-percent-rbc-says-floor-put-in\" target=\"_blank\">earlier this week</a> upgraded the stock to Outperform and raised his price target to $15 from $13, points to new CEO Larry Culp's <a href=\"https://seekingalpha.com/news/3395332-ge-lays-pay-package-new-ceo-culp\" target=\"_blank\">compensation package</a>, largely tied to outsized stock gains, as a <a href=\"https://www.streetinsider.com/Analyst+Comments/Market+Likes+that+GE+%28GE%29+CEO+Culps+Pay+Package+is+Largely+Tied+to+Outsized+Stock+Gains+-+RBC/14679977.html\" target=\"_blank\">positive</a>.</li>     <li>\"The bottom line is that this overweighting of GE&rsquo;s stock price as a benchmark for Mr. Culp&rsquo;s incentive comp reinforces our view that he would not have taken on this job without clear line-of-sight on the turnaround strategy,\" Dray writes.</li>     <li>Dray sees GE's next potential catalyst as the highly-anticipated Q3 earnings report on Oct. 25, which will provide a first look at Culp's operating strategy and priorities as GE&rsquo;s newest CEO.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395554\" data-linked=\"Market likes GE CEO Culp&#39;s stock-heavy pay package, RBC analyst says\" data-tweet=\"$GE - Market likes GE CEO Culp&#39;s stock-heavy pay package, RBC analyst says https://seekingalpha.com/news/3395554-market-likes-ge-ceo-culps-stock-heavy-pay-package-rbc-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3395554-market-likes-ge-ceo-culps-stock-heavy-pay-package-rbc-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395551\" data-ts=\"1538762424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SJT\" target=\"_blank\">SJT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395551-energy-materials-top-gainers-losers-of-2-00-pm-10-05-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials  - Top Gainers / Losers as of 2:00 PM (10/05/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SJT' title='San Juan Basin Royalty Trust'>SJT</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc Ordinary Sh'>HBM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GLF' title='GulfMark Offshore, Inc.'>GLF</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BXE' title='Bellatrix Exploration Ltd'>BXE</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395551\" data-linked=\"Energy/Materials  - Top Gainers / Losers as of 2:00 PM (10/05/2018)\" data-tweet=\"$SJT $SJT $IGC - Energy/Materials - Top Gainers / Losers as of 2:00 PM (10/05/2018) https://seekingalpha.com/news/3395551-energy-materials-top-gainers-losers-of-2-00-pm-10-05-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3395551-energy-materials-top-gainers-losers-of-2-00-pm-10-05-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395543\" data-ts=\"1538759583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395543-cheddar-snap-losing-vp-of-marketing-in-latest-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheddar: Snap losing VP of Marketing in latest exit</a></h4><ul>   <li>Snap's (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color='red'>-1.7%</font>) VP of Marketing is <a href=\"https://cheddar.com/videos/snap-vp-marketing-steve-labella-leaving-company\" target=\"_blank\">exiting the company</a>, Cheddar reports.</li>    <li>That's the latest in a recent string of departures.</li>    <li>Steve LaBella joined the company in May 2016 and led the company's efforts through this year's first national TV campaign, and told employees last week that he's departing, according to Alex Heath.</li>    <li>He'll remain through the end of November.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395328-snaps-spiegel-memo-still-pursuing-break-even-year-shares-plus-2_6-percent\" target=\"_blank\">Snap's Spiegel memo: Still pursuing break-even this year; shares +2.6%</a> (Oct. 04 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395543\" data-linked=\"Cheddar: Snap losing VP of Marketing in latest exit\" data-tweet=\"$SNAP - Cheddar: Snap losing VP of Marketing in latest exit https://seekingalpha.com/news/3395543-cheddar-snap-losing-vp-of-marketing-in-latest-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3395543-cheddar-snap-losing-vp-of-marketing-in-latest-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395541\" data-ts=\"1538759428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYL\" target=\"_blank\">LYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395541-financials-top-5-gainers-losers-of-1-10-pm-10-05-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:10 PM (10/05/2018)</a></h4><ul><li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/LYL' title='Dragon Victory International Limited'>LYL</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CMCT' title='CIM Commercial Trust Corp.'>CMCT</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SIR' title='Select Income REIT'>SIR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/VBTX' title='Veritex Holdings'>VBTX</a> <font color='green'>+6%</font>.</li><li><b>Losers: </b><a href='https://seekingalpha.com/symbol/CASH' title='Meta Financial Group, Inc.'>CASH</a> <font color='red'>-67%</font>. <a href='https://seekingalpha.com/symbol/EVER' title='EverQuote'>EVER</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/XIN' title='Xinyuan Real Estate Co., Ltd.'>XIN</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395541\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:10 PM (10/05/2018)\" data-tweet=\"$LYL $LYL $MHLD - Financials - Top 5 Gainers / Losers as of 1:10 PM (10/05/2018) https://seekingalpha.com/news/3395541-financials-top-5-gainers-losers-of-1-10-pm-10-05-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3395541-financials-top-5-gainers-losers-of-1-10-pm-10-05-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395537\" data-ts=\"1538758595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWPH\" target=\"_blank\">GWPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395537-gw-pharma-raises-345m-in-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GW Pharma raises $345M in equity offering</a></h4><ul><li>GW Pharmaceuticals (<a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a> <font color='red'>-2.1%</font>) has <a href=\"https://seekingalpha.com/pr/17292420-gw-pharmaceuticals-plc-announces-closing-public-offering-adss-raising-gross-proceeds-345\" target=\"_blank\">closed</a> its public offering of 1.9M American Depositary Shares (ADSs) and the full exercise of underwriters' over-allotment of 285K additional ADSs at $158 per ADS. Gross proceeds were ~$345M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395537\" data-linked=\"GW Pharma raises $345M in equity offering\" data-tweet=\"$GWPH - GW Pharma raises $345M in equity offering https://seekingalpha.com/news/3395537-gw-pharma-raises-345m-in-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3395537-gw-pharma-raises-345m-in-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395535\" data-ts=\"1538758286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTXI\" target=\"_blank\">GTXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395535-midday-gainers-losers-10-05-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (10/05/2018)</a></h4><ul><li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/GTXI' title='GTx, Inc.'>GTXI</a> <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics'>VTVT</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/EPIX' title='ESSA Pharma, Inc.'>EPIX</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/LEVB' title='Level Brands, Inc.'>LEVB</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ASNS' title='Arsanis, Inc.'>ASNS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CHEF' title='Chefs&#39; Warehouse'>CHEF</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/AUTL' title='Autolus Therapeutics'>AUTL</a> <font color='green'>+12%</font>.</li><li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/HSGX' title='Histogenics Corporation'>HSGX</a>&nbsp;<font color='red'>-42%</font>. <a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a>&nbsp;<font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/KMPH' title='KemPharm'>KMPH</a>&nbsp;<font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a>&nbsp;<font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/CUTR' title='Cutera, Inc.'>CUTR</a>&nbsp;<font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/LMAT' title='LeMaitre Vascular, Inc.'>LMAT</a>&nbsp;<font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a>&nbsp;<font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a>&nbsp;<font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/MYE' title='Myers Industries, Inc.'>MYE</a>&nbsp;<font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/NVLN' title='Novelion Therapeutics, Inc.'>NVLN</a>&nbsp;<font color='red'>-17%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395535\" data-linked=\"Midday Gainers / Losers (10/05/2018)\" data-tweet=\"$GTXI $ONCT $SGH - Midday Gainers / Losers (10/05/2018) https://seekingalpha.com/news/3395535-midday-gainers-losers-10-05-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3395535-midday-gainers-losers-10-05-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395536\" data-ts=\"1538758092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395536-youtube-tv-boosts-cloud-dvr-features-after-user-feedback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YouTube TV boosts cloud DVR features after user feedback</a></h4><ul>   <li>YouTube TV (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-1.6%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='red'>-1.6%</font>) is responding to users with <a href=\"https://www.fiercevideo.com/video/youtube-tv-makes-upgrades-to-its-cloud-dvr\" target=\"_blank\">upgrades to its cloud DVR service</a>, enhancing options for users storing programs for later.</li>    <li>Subscribers will now get full control to pause, rewind and fast-forward at any point in playback.</li>    <li>Also, if an on-demand version was available for a show that users had recorded, YouTube TV used to switch those (and their unskippable commercials) in for subscribers' recorded copies. Now users can choose their recording and fast-forward through commercials.</li>    <li>Content from AMC Networks, Disney, Fox TV, NBCUniversal and Turner is now available for immediate DVR playback, the company said.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395536\" data-linked=\"YouTube TV boosts cloud DVR features after user feedback\" data-tweet=\"$GOOG $GOOG $GOOGL - YouTube TV boosts cloud DVR features after user feedback https://seekingalpha.com/news/3395536-youtube-tv-boosts-cloud-dvr-features-after-user-feedback?source=tweet\" data-url=\"https://seekingalpha.com/news/3395536-youtube-tv-boosts-cloud-dvr-features-after-user-feedback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395533\" data-ts=\"1538756981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395533-tesla-follows-musk-down-rabbit-hole\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla follows Musk down the rabbit hole</a></h4><ul> <li>Shares of Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) are <font color='red'>down 6.28%</font> as investors weigh just how far down the rabbit hole Elon Musk went yesterday by tweeting an insult at the SEC.</li> <li>On Wall Street, several analysts say that the SEC could in theory pull back the settlement offer due to the Musk tweet, while Bond Angle's Vicki Bryan notes that the judge in the case could use the tweet as an example of how the settlement offer didn't go far enough in addressing \"management deficiencies\" at Tesla. The latest <a href=\"https://twitter.com/CGasparino/status/1048243305727873025\" target=\"_blank\">report</a> from Fox Business Network's Charlie Gasparino is that SEC sources indicate they are \"largely powerless\" to enforce the admit/deny part of the Musk settlement because the judge hasn't approved it yet. Finally a former SEC chairman is weighing in on the development. \"It is an indication of impetuousness, but I don&rsquo;t think it&rsquo;s a securities law violation. It&rsquo;s just plain bad taste,\" says Harvey Pitt.</li><li>Adding it all up, it looks like the SEC wildcard is going to be around for a while.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395533\" data-linked=\"Tesla follows Musk down the rabbit hole\" data-tweet=\"$TSLA - Tesla follows Musk down the rabbit hole https://seekingalpha.com/news/3395533-tesla-follows-musk-down-rabbit-hole?source=tweet\" data-url=\"https://seekingalpha.com/news/3395533-tesla-follows-musk-down-rabbit-hole\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>203&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395531\" data-ts=\"1538756679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395531-twitter-turns-negative-bt-gains-amid-greenlight-position-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter turns negative, BT gains, amid Greenlight position news</a></h4><ul>   <li>Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) has turned negative on the day, <font color='red'>down 0.3%</font> after earlier <font color='green'>gains of 2.6%</font>, after a letter from David Einhorn's Greenlight Capital shows the firm <a href=\"https://seekingalpha.com/news/3395530-einhorn-blows-numerous-positions\" target=\"_blank\">exited its long position</a>.</li>    <li>Meanwhile BT Group (NYSE:<a href='https://seekingalpha.com/symbol/BT' title='BT Group plc'>BT</a>) is <font color='green'>up 1.2%</font> in U.S. trading after the disclosure that Greenlight added a position there.</li>    <li>And Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>), already in negative ground for most of the day, is <font color='red'>down 2%</font>; Greenlight exited its long position there as well.</li><li>Greenlight lost 9.1% for the quarter, bringing YTD performance to -25.7%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395531\" data-linked=\"Twitter turns negative, BT gains, amid Greenlight position news\" data-tweet=\"$TWTR $TWTR $BT - Twitter turns negative, BT gains, amid Greenlight position news https://seekingalpha.com/news/3395531-twitter-turns-negative-bt-gains-amid-greenlight-position-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3395531-twitter-turns-negative-bt-gains-amid-greenlight-position-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395525\" data-ts=\"1538755268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFBG-OLD\" target=\"_blank\">DFBG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395525-consumer-top-gainers-losers-of-12-00-pm-10-05-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (10/05/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DFBG-OLD' title='Differential Brands Group Inc.'>DFBG-OLD</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MYE' title='Myers Industries, Inc.'>MYE</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/DLPH' title='Delphi Technologies PLC'>DLPH</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDs TEA'>DTEA</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395525\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (10/05/2018)\" data-tweet=\"$DFBG-OLD $DFBG-OLD $KNDI - Consumer - Top Gainers / Losers as of 12:00 PM (10/05/2018) https://seekingalpha.com/news/3395525-consumer-top-gainers-losers-of-12-00-pm-10-05-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3395525-consumer-top-gainers-losers-of-12-00-pm-10-05-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395521\" data-ts=\"1538754827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESTC\" target=\"_blank\">ESTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395521-elastic-soars-on-first-trading-day\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elastic soars on first trading day</a></h4><ul><li>Elastic (NYSE:<a href='https://seekingalpha.com/symbol/ESTC' title='Elastic'>ESTC</a>) shares open their first day at $70, up from the $36 pricing, a gain of&nbsp;<font color='green'>about 94%</font>.</li><li>The search software company competes with Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='red'>-1.6%</font>), Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-1.6%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='red'>-1.6%</font>), and Splunk (<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a> <font color='red'>-1.4%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395342-elastic-announces-pricing-ipo\" target=\"_blank\">Elastic announces pricing of IPO</a> (Oct. 4)</li><li>Post updated with opening price.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395521\" data-linked=\"Elastic soars on first trading day\" data-tweet=\"$ESTC $ESTC $AMZN - Elastic soars on first trading day https://seekingalpha.com/news/3395521-elastic-soars-on-first-trading-day?source=tweet\" data-url=\"https://seekingalpha.com/news/3395521-elastic-soars-on-first-trading-day\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395516\" data-ts=\"1538753337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395516-rate-worries-sink-stocks-nasdaq-drops-another-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rate worries sink stocks; Nasdaq drops another 1%</a></h4><ul><li>This morning's <a href=\"https://seekingalpha.com/news/3395439-guts-jobs-report-better-headline-yields-shoot-higher\" target=\"_blank\">mostly strong jobs numbers </a>did nothing to give the bond bears pause, with the 10-year Treasury yield carving out a new multi-year high at 3.22%.</li><li>The particularly perky tech sector is again bearing the brunt of the selling - the Nasdaq's&nbsp;<font color='red'>1% decline&nbsp;</font>is twice that of the S&amp;P 500. Among the large decliners: Netflix&nbsp;<font color='red'>-4.6%</font>, Nvidia&nbsp;<font color='red'>-2.4%</font>, IBM, Intel, and Texas Instruments all&nbsp;<font color='red'>down 2%</font>.</li><li>Bright spots: The healthcare sector is flat on the session, and GE is&nbsp;<font color='green'>higher by another 4.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395516\" data-linked=\"Rate worries sink stocks; Nasdaq drops another 1%\" data-tweet=\"Rate worries sink stocks; Nasdaq drops another 1% https://seekingalpha.com/news/3395516-rate-worries-sink-stocks-nasdaq-drops-another-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3395516-rate-worries-sink-stocks-nasdaq-drops-another-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395509\" data-ts=\"1538752115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDEN\" target=\"_blank\">GDEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395509-deutsche-bank-likes-growth-track-golden-entertainment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank likes growth track at Golden Entertainment</a></h4><ul> <li>Golden Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/GDEN' title='Golden Entertainment, Inc.'>GDEN</a>) moves <font color='green'>up 2.2%</font> after Deutsche Bank initiates coverage with a Buy rating.</li> <li>Analyst Danny Valoy calls the casino stock as \"golden opportunity hiding in plain sight\" on a very positive view of the growth potential.</li> <li>DB's price target of $40 on Golden Entertainment reps +50% upside potential for shares. The 52-week high for GDEN is $34.75.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3395509\" data-linked=\"Deutsche Bank likes growth track at Golden Entertainment\" data-tweet=\"$GDEN - Deutsche Bank likes growth track at Golden Entertainment https://seekingalpha.com/news/3395509-deutsche-bank-likes-growth-track-golden-entertainment?source=tweet\" data-url=\"https://seekingalpha.com/news/3395509-deutsche-bank-likes-growth-track-golden-entertainment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395507\" data-ts=\"1538751648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTVT\" target=\"_blank\">VTVT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395507-healthcare-top-5-gainers-losers-of-11-00-10-05-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (10/05/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics'>VTVT</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/GTXI' title='GTx, Inc.'>GTXI</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/ASNS' title='Arsanis, Inc.'>ASNS</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/VBIV' title='VBI Vaccines'>VBIV</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HSGX' title='Histogenics Corporation'>HSGX</a> <font color='red'>-39%</font>. <a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/KMPH' title='KemPharm'>KMPH</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/CUTR' title='Cutera, Inc.'>CUTR</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/LMAT' title='LeMaitre Vascular, Inc.'>LMAT</a> <font color='red'>-19%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395507\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (10/05/2018)\" data-tweet=\"$VTVT $VTVT $ONCT - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (10/05/2018) https://seekingalpha.com/news/3395507-healthcare-top-5-gainers-losers-of-11-00-10-05-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3395507-healthcare-top-5-gainers-losers-of-11-00-10-05-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395506\" data-ts=\"1538751586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLCA\" target=\"_blank\">SLCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395506-u-s-silica-forecasts-lower-expected-growth-in-q3-sand-volumes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Silica forecasts lower than expected growth in Q3 sand volumes</a></h4><ul>     <li>U.S. Silica (<a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='red'>-1.7%</font>) is lower after saying its Q3 sand proppant sales volumes <a href=\"https://seekingalpha.com/pr/17291958-u-s-silicas-sandbox-unit-receives-final-judgment-arrows\" target=\"_blank\">rose 10% Q/Q</a>, which is down from its previously provided guidance of 20-25% growth as it ramped new capacity in west Texas and brought its Brownfield expansion projects fully online.</li>     <li>SLCA says it expects its Northern White proppant pricing will be lower sequentially, \"given the widely reported slowdown in well completions in the back half of Q3 and the continued growth of in-basin sand capacity,\" but also says west Texas volumes and pricing held up well during the quarter, despite the 12M-plus tons of high cost competitor Northern White capacity coming off line.</li>     <li>Also, SLCA says a Texas court entered final judgment in favor of its SandBox subsidiary, requiring Arrows Up to pay SandBox $49.2M in damages.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395506\" data-linked=\"U.S. Silica forecasts lower than expected growth in Q3 sand volumes\" data-tweet=\"$SLCA - U.S. Silica forecasts lower than expected growth in Q3 sand volumes https://seekingalpha.com/news/3395506-u-s-silica-forecasts-lower-expected-growth-in-q3-sand-volumes?source=tweet\" data-url=\"https://seekingalpha.com/news/3395506-u-s-silica-forecasts-lower-expected-growth-in-q3-sand-volumes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395505\" data-ts=\"1538751520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNS\" target=\"_blank\">ASNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395505-arsanis-up-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arsanis up 19%</a></h4><ul><li>Thinly traded nano cap Arsanis (<a href='https://seekingalpha.com/symbol/ASNS' title='Arsanis, Inc.'>ASNS</a> <font color='green'>+18.8%</font>) is up on a healthy 17x surge in volume on no particular news other than it's another tiny biotech breakout. Shares were up over<font color='green'> 60%</font>&nbsp;intraday before retracing.</li><li>At the end of June, it had $49.9M in cash and equivalents while operations consumed $25.7M in H1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395505\" data-linked=\"Arsanis up 19%\" data-tweet=\"$ASNS $XFOR - Arsanis up 19% https://seekingalpha.com/news/3395505-arsanis-up-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3395505-arsanis-up-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395498\" data-ts=\"1538750235\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYTU\" target=\"_blank\">AYTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395498-aytu-bio-down-33-ahead-of-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aytu Bio down 33% ahead of equity offering</a></h4><ul><li>Thinly traded nano cap Aytu BioScience (<a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a> <font color='red'>-33.2%</font>) is down on more than a 7x surge in volume in reaction to its planned <a href=\"https://www.sec.gov/Archives/edgar/data/1385818/000121390018013575/fs1mefoct18_aytubioscience.htm\" target=\"_blank\">$5.1M equity offering</a>, more than double the size that it filed for a week ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392891-aytu-bio-sets-terms-equity-offering-shares-6-percent-hours\" target=\"_blank\">Aytu Bio sets terms for equity offering; shares down 6% after hours</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395498\" data-linked=\"Aytu Bio down 33% ahead of equity offering\" data-tweet=\"$AYTU - Aytu Bio down 33% ahead of equity offering https://seekingalpha.com/news/3395498-aytu-bio-down-33-ahead-of-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3395498-aytu-bio-down-33-ahead-of-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395497\" data-ts=\"1538749902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395497-discoveryplus-2_2-evercore-boosts-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Discovery +2.2% as Evercore boosts target</a></h4><ul>   <li>Discovery (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>) is <font color='green'>up 2.2%</font> and tapping three-year highs after a boost to its price target at Evercore ISI.</li>    <li>The firm raised its target to $38 from $32, implying 12.2% upside from today's higher price.</li>    <li>Ratings are improving and the company has \"an attractive fundamental setup\" going into the coming year and a half, analyst Vijay Jayant says. New distribution deals with Hulu and Sling TV means that the company's networks are now carried on all major virtual MVPD platforms outside of YouTube TV, Jayant notes. (h/t Bloomberg)</li>    <li>Shares have been on a run for months, <font color='green'>up 46.6%</font> over the past six.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395497\" data-linked=\"Discovery +2.2% as Evercore boosts target\" data-tweet=\"$DISCA $DISCB $DISCK - Discovery +2.2% as Evercore boosts target https://seekingalpha.com/news/3395497-discoveryplus-2_2-evercore-boosts-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3395497-discoveryplus-2_2-evercore-boosts-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395494\" data-ts=\"1538749527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMS\" target=\"_blank\">ADMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395494-adamas-pharma-down-10-on-gocovri-headwinds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamas Pharma down 10% on Gocovri headwinds</a></h4><ul><li>Adamas Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a> <font color='red'>-9.5%</font>) slumps on modestly higher volume in early trade following a downgrade to Neutral at BofA/Merrill Lynch. Analyst Tazeen Ahmad says a survey of doctors showed a higher-than-expected dropout rate for Parkinson's med GOCOVRI (amantadine) due to the high cost and difficulty in securing prior authorizations from payers.</li><li>There is also looming competition from <a href=\"https://seekingalpha.com/news/3390550-osmotica-pharmaceuticals-deck-ipo\" target=\"_blank\">pending IPO</a>&nbsp;Osmotica Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/OSMT' title='Osmotica Pharmaceuticals plc'>OSMT</a>), which plans to launch an extended-release formulation of amantadine, branded as <a href=\"https://www.osmolex.com/\" target=\"_blank\">Osmolex ER</a>, this quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395494\" data-linked=\"Adamas Pharma down 10% on Gocovri headwinds\" data-tweet=\"$ADMS $ADMS $OSMT - Adamas Pharma down 10% on Gocovri headwinds https://seekingalpha.com/news/3395494-adamas-pharma-down-10-on-gocovri-headwinds?source=tweet\" data-url=\"https://seekingalpha.com/news/3395494-adamas-pharma-down-10-on-gocovri-headwinds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395490\" data-ts=\"1538749148\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABCD\" target=\"_blank\">ABCD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395490-cambium-learning-groupplus-4_3-on-reported-buyer-bids\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cambium Learning Group +4.3% on reported buyer bids</a></h4><ul><li>        Cambium Learning Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ABCD' title='Cambium Learning Group, Inc.'>ABCD</a>)&nbsp;<font color='green'>gains 4.3%</font>&nbsp;to $11.78 on reports that the company is collecting final bids from interested buyers, five months after the company announced a strategic review that included sale consideration.</li><li>               Source: StreetAccount, citing rumored Dealreporter comments. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3395490\" data-linked=\"Cambium Learning Group +4.3% on reported buyer bids\" data-tweet=\"$ABCD - Cambium Learning Group +4.3% on reported buyer bids https://seekingalpha.com/news/3395490-cambium-learning-groupplus-4_3-on-reported-buyer-bids?source=tweet\" data-url=\"https://seekingalpha.com/news/3395490-cambium-learning-groupplus-4_3-on-reported-buyer-bids\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395489\" data-ts=\"1538748782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEEV\" target=\"_blank\">VEEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395489-needham-raises-veeva-target-after-analyst-day\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham raises its Veeva target after the analyst day</a></h4><ul><li>        Needham raises its Veeva Systems (NYSE:<a href='https://seekingalpha.com/symbol/VEEV' title='Veeva Systems Inc.'>VEEV</a>) target from $100 to $110 after the company&rsquo;s analyst day.</li><li>               Needham believes the impressive product portfolio that Veeva continues to develop has positioned the company to maintain 20%+ Y/Y subscription revenue growth beyond CY20-21.&nbsp;</li><li>               The firm thinks Commercial and Vault product penetration with large enterprise customers is low at 25% and 10%, respectively, which supports Veeva&rsquo;s target of a $1B revenue run-rate during CY19.&nbsp;</li><li>               Source: Briefing.com.&nbsp;</li><li>               Veeva shares are&nbsp;<font color='green'>up 2%</font>&nbsp;to $100.23.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3395489\" data-linked=\"Needham raises its Veeva target after the analyst day\" data-tweet=\"$VEEV - Needham raises its Veeva target after the analyst day https://seekingalpha.com/news/3395489-needham-raises-veeva-target-after-analyst-day?source=tweet\" data-url=\"https://seekingalpha.com/news/3395489-needham-raises-veeva-target-after-analyst-day\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395488\" data-ts=\"1538748688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CELTF\" target=\"_blank\">CELTF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395488-centaminminus-11-quarterly-gold-production-drops-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Centamin -11% as quarterly gold production drops 25%</a></h4><ul>     <li>Centamin (<a href='https://seekingalpha.com/symbol/CELTF' title='Centamin PLC'>OTCPK:CELTF</a> <font color='red'>-11.3%</font>) plunges at the open after the gold miner cut its annual production target after reporting a <a href=\"http://www.proactiveinvestors.co.uk/companies/news/206457/gold-miner-centamin-slashes-full-year-production-target-as-quarterly-output-slumps-206457.html\" target=\"_blank\">25% Y/Y decline in Q3 output</a> from its flagship Sukari mine in Egypt.</li>     <li>The miner reported total gold production of 117.7K oz. in the quarter vs. 156.5K oz. in the year-ago period, citing delays to planned operational improvements, although output was higher than Q2's 92.8K oz.</li>     <li>Centamin now forecasts annual production of ~480K oz., down from May guidance of 505K-515K oz. and its 580K oz. target set at the start of the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395488\" data-linked=\"Centamin -11% as quarterly gold production drops 25%\" data-tweet=\"$CELTF - Centamin -11% as quarterly gold production drops 25% https://seekingalpha.com/news/3395488-centaminminus-11-quarterly-gold-production-drops-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3395488-centaminminus-11-quarterly-gold-production-drops-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395487\" data-ts=\"1538748680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBSFY\" target=\"_blank\">UBSFY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395487-ubisoft-top-pick-in-berenberg-launch-of-videogame-coverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ubisoft top pick in Berenberg launch of videogame coverage</a></h4><ul>   <li>A \"deeply excited\" Berenberg opens coverage on the videogame sector with an eye to growth and margin expansion ahead.</li>    <li>Among catalysts that should lift all boats: mobile, in-game revenues, esports, subscriptions, and developments in the Chinese market.</li>    <li>Ubisoft (<a href=\"http://seekingalpha.com/symbol/UBSFY\" target=\"_blank\">UBSFY</a> <font color='red'>-1.7%</font>), maker of game series <i>Assassin's Creed</i> and <i>Far Cry,</i> is the firm's top pick based on its growth outlook.</li>    <li>Meanwhile among two American giants, Berenberg has a Buy rating on Electronic Arts (<a href=\"http://seekingalpha.com/symbol/EA\" target=\"_blank\">EA</a> <font color='green'>+0.8%</font>) while it's rating Activision Blizzard (<a href=\"http://seekingalpha.com/symbol/ATVI\" target=\"_blank\">ATVI</a> <font color='red'>-0.7%</font>) a Hold, considering it high quality but fully valued.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395487\" data-linked=\"Ubisoft top pick in Berenberg launch of videogame coverage\" data-tweet=\"$UBSFY $UBSFY $EA - Ubisoft top pick in Berenberg launch of videogame coverage https://seekingalpha.com/news/3395487-ubisoft-top-pick-in-berenberg-launch-of-videogame-coverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3395487-ubisoft-top-pick-in-berenberg-launch-of-videogame-coverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395482\" data-ts=\"1538748021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHEF\" target=\"_blank\">CHEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395482-chefs-warehouseplus-9-after-index-call-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chef&#39;s Warehouse +9% after index call-up</a></h4><ul> <li>Chefs' Warehouse (NASDAQ:<a href='https://seekingalpha.com/symbol/CHEF' title='Chefs&#39; Warehouse'>CHEF</a>) is now <font color='green'>up 9.4%</font> after the company is tapped to replace Penn National Gaming in the S&amp;P SmallCap 600 Index.</li> <li>Shares of CHEF&nbsp;are less than a dollar from their all-time high of $38.20 off the index inclusion news.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395324-chef-plus-6_3-percent-move-smallcap-600-ftnt-s-and-p-500\" target=\"_blank\">CHEF +6.3% on move to SmallCap 600; FTNT to S&amp;P 500</a> (Oct. 4)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3395482\" data-linked=\"Chef&#39;s Warehouse +9% after index call-up\" data-tweet=\"$CHEF - Chef&#39;s Warehouse +9% after index call-up https://seekingalpha.com/news/3395482-chefs-warehouseplus-9-after-index-call-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3395482-chefs-warehouseplus-9-after-index-call-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395477\" data-ts=\"1538747548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCB\" target=\"_blank\">ARCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395477-wolfe-research-warns-on-five-trucking-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wolfe Research warns on five trucking stocks</a></h4><ul> <li>Wolfe Research turns negative on the trucking sector on concerns over spot rates.</li> <li>A survey conducted by the firm indicates shipper pricing expectations are swinging lower, per Bloomberg.</li> <li>Within the sector, ArcBest (<a href='https://seekingalpha.com/symbol/ARCB' title='ArcBest Corporation'>ARCB</a> <font color='red'>-8.8%</font>), Covenant Transportation (<a href='https://seekingalpha.com/symbol/CVTI' title='Covenant Transportation Group, Inc.'>CVTI</a> <font color='red'>-5.1%</font>), Landstar System (<a href='https://seekingalpha.com/symbol/LSTR' title='Landstar System, Inc.'>LSTR</a> <font color='red'>-2.2%</font>), Werner Enterprises (<a href='https://seekingalpha.com/symbol/WERN' title='Werner Enterprises, Inc.'>WERN</a> <font color='red'>-3%</font>) and Schneider National (<a href='https://seekingalpha.com/symbol/SNDR' title='Schneider National'>SNDR</a> <font color='red'>-3.9%</font>) are singled out as at pricing risk. All five trucking stocks are downgraded by Wolfe to Underperform from Peer Perform.</li> <li>\"We have not assumed a recession in our models but expect slower freight volume and pricing growth the next 2 years,\" writes the Wolfe team on the freight/economic cycle.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395477\" data-linked=\"Wolfe Research warns on five trucking stocks\" data-tweet=\"$ARCB $ARCB $CVTI - Wolfe Research warns on five trucking stocks https://seekingalpha.com/news/3395477-wolfe-research-warns-on-five-trucking-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3395477-wolfe-research-warns-on-five-trucking-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395476\" data-ts=\"1538747384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGH\" target=\"_blank\">SGH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395476-analysts-adjust-smart-global-targets-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts adjust SMART Global targets after earnings beat</a></h4><ul><li>        Analysts adjust SMART Global Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a>) targets after yesterday&rsquo;s earnings report beat estimates and provided guidance upside.</li><li>               Stifel reiterates its Buy rating and raises its SMART Global target by a dollar to $62 or 9x FY19 EPS. Analyst Kevin Cassidy mentions that guidance for sequential growth in all product lines goes against the bear case. Demand for specialty memory and the newly acquired Penguin Computing products look strong.&nbsp;</li><li>               Deutsche Bank maintains a Buy but lowers the target from $60 to $50. Analyst Sidney Ho says the results should reduce concerns that softening memory will substantially dent financials and was encouraged by management confidence that 2H should have solid seasonal growth. Ho continues to see the risk/reward as favorable with shares only trading at about 4x CY19 EPS.&nbsp;</li><li>               Source: StreetAccount.&nbsp;</li><li>               SGH shares are&nbsp;<font color='green'>up 27.8%</font>&nbsp;to $34.73.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395291-smart-global-holdings-reports-q4-beats-upside-guidance\" target=\"_blank\">SMART Global Holdings reports Q4 beats, upside guidance</a> (Oct. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395476\" data-linked=\"Analysts adjust SMART Global targets after earnings beat\" data-tweet=\"$SGH - Analysts adjust SMART Global targets after earnings beat https://seekingalpha.com/news/3395476-analysts-adjust-smart-global-targets-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3395476-analysts-adjust-smart-global-targets-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395466\" data-ts=\"1538746491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPGP\" target=\"_blank\">IPGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395466-laser-makers-under-early-pressure-after-softer-guidance-from-ipg-photonics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Laser makers under early pressure after softer guidance from IPG Photonics</a></h4><ul><li>Laser companies are under modest pressure out of the gate in apparent sympathy with IPG Photonics (<a href='https://seekingalpha.com/symbol/IPGP' title='IPG Photonics Corporation'>IPGP</a> <font color='red'>-9.9%</font>) after it lowered Q3 guidance.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/COHR' title='Coherent, Inc.'>COHR</a> <font color='red'>-0.9%</font>)(<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a> <font color='red'>-2.4%</font>)(<a href='https://seekingalpha.com/symbol/LASR' title='nLIGHT, Inc.'>LASR</a>&nbsp;<font color='red'>-5.0%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395414-ipg-photonics-announces-preliminary-q3-results\" target=\"_blank\">IPG Photonics announces preliminary Q3 results</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395466\" data-linked=\"Laser makers under early pressure after softer guidance from IPG Photonics\" data-tweet=\"$IPGP $IPGP $COHR - Laser makers under early pressure after softer guidance from IPG Photonics https://seekingalpha.com/news/3395466-laser-makers-under-early-pressure-after-softer-guidance-from-ipg-photonics?source=tweet\" data-url=\"https://seekingalpha.com/news/3395466-laser-makers-under-early-pressure-after-softer-guidance-from-ipg-photonics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395462\" data-ts=\"1538746041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMPH\" target=\"_blank\">KMPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395462-kempharm-prices-stock-offering-3-shares-down-33-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KemPharm prices stock offering at $3; shares down 33% premarket</a></h4><ul><li>Thinly traded nano cap KemPharm (NASDAQ:<a href='https://seekingalpha.com/symbol/KMPH' title='KemPharm'>KMPH</a>) slumps&nbsp;<font color='red'>33%</font>&nbsp;premarket in reaction to its<a href=\"https://seekingalpha.com/pr/17292366-kempharm-announces-pricing-public-offering-common-stock\" target=\"_blank\"> public offering</a> of ~8.3M shares of common stock at $3/share. Underwriters over-allotment is an additional ~1.3M shares. Closing date is October 10.</li><li>Yesterday's close was $4.18.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395462\" data-linked=\"KemPharm prices stock offering at $3; shares down 33% premarket\" data-tweet=\"$KMPH - KemPharm prices stock offering at $3; shares down 33% premarket https://seekingalpha.com/news/3395462-kempharm-prices-stock-offering-3-shares-down-33-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3395462-kempharm-prices-stock-offering-3-shares-down-33-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395461\" data-ts=\"1538745955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTXI\" target=\"_blank\">GTXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395461-premarket-gainers-of-9-05-10-05-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (10/05/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/GTXI' title='GTx, Inc.'>GTXI</a> <font color='green'>+55%</font>&nbsp;on robust volume on <a href=\"https://seekingalpha.com/news/3395435-gtx-51-percent-premarket\" target=\"_blank\">no readily available news</a>.</li><li><a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics'>VTVT</a> <font color='green'>+44%</font>.</li><li><a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a> <font color='green'>+13%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3395281-smart-global-holdings-beats-0_06-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/EMKR' title='EMCORE Corporation'>EMKR</a> <font color='green'>+10%</font>&nbsp;on Q4 preliminary <a href=\"https://seekingalpha.com/news/3395295-emcore-reports-preliminary-q4-results-shares-plus-1_5-percent-ah\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a> <font color='green'>+7%</font>&nbsp;on preliminary Q3 <a href=\"https://seekingalpha.com/news/3395388-himax-plus-5_8-percent-upside-preliminary-q3-results\" target=\"_blank\">results</a>.</li><li><a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a> <font color='green'>+5%</font>&nbsp;on strong HERO7 Black week-one <a href=\"https://seekingalpha.com/news/3395384-gopro-plus-7_8-percent-strong-hero7-black-week-one-sales\" target=\"_blank\">sales</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395461\" data-linked=\"Premarket Gainers as of 9:05 am (10/05/2018)\" data-tweet=\"$GTXI $ONCT $VTVT - Premarket Gainers as of 9:05 am (10/05/2018) https://seekingalpha.com/news/3395461-premarket-gainers-of-9-05-10-05-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3395461-premarket-gainers-of-9-05-10-05-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395457\" data-ts=\"1538745680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395457-mimedx-down-6-premarket-on-critical-wsj-article\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx down 6% premarket on critical WSJ article</a></h4><ul><li>Embattled MiMedx Group (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a>) slips&nbsp;<font color='red'>6%</font>&nbsp;premarket on light volume in apparent reaction to a <a href=\"https://www.wsj.com/articles/mimedx-kept-cheaper-products-out-of-its-offerings-to-va-hospitals-1538731801?mod=e2tw\" target=\"_blank\">WSJ article</a> saying the company limited the range of products it offered to federal customers, including the Veterans Administration, to its most expensive offerings.</li><li>The company allegedly had one set of products for federal customers and another set for private buyers. At the VA, the company did not offer the smaller sizes of two popular products it offered elsewhere, forcing the VA to purchase larger, more expensive versions. Its EpiFix injectable is one example. The smallest size for federal customers is 40 mg costing $725 while private doctors can acquire the 20 mg size for $225.</li><li>The company's dealings with healthcare providers at government-run hospitals are also under scrutiny. Last month, a grand jury in Georgia heard testimony about its financial ties to a surgeon at the Army's medical center at Fort Gordon.</li><li>Former CEO Parker Petit and several other former executives were forced out due \"conduct detrimental to the business.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392045-mimedx-treat-executive-terminations-cause-shares-11-percent-premarket\" target=\"_blank\">MiMedx to treat executive terminations as \"for cause\" - shares down 11% premarket</a> (Sept. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395457\" data-linked=\"MiMedx down 6% premarket on critical WSJ article\" data-tweet=\"$MDXG - MiMedx down 6% premarket on critical WSJ article https://seekingalpha.com/news/3395457-mimedx-down-6-premarket-on-critical-wsj-article?source=tweet\" data-url=\"https://seekingalpha.com/news/3395457-mimedx-down-6-premarket-on-critical-wsj-article\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395454\" data-ts=\"1538745088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYSCF\" target=\"_blank\">LYSCF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395454-lynasplus-10-after-head-of-malaysia-review-sounds-conciliatory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lynas +10% after head of Malaysia review sounds more conciliatory</a></h4><ul>     <li>Rare earth minerals miner Lynas (<a href='https://seekingalpha.com/symbol/LYSCF' title='Lynas Corp. Ltd.'>OTCPK:LYSCF</a>) jumped 10% in Australian trading after the head of an environmental review into the company&rsquo;s Malaysian plant was quoted as <a href=\"https://sg.news.yahoo.com/lynas-shares-jump-malaysia-review-054319004.html\" target=\"_blank\">sounding more conciliatory</a> than previously.</li><li>The review chairman said her environmental audit committee  acknowledged Lynas and its employees were important stakeholders in the  review, and said the review would be made  transparent, according to a report in Malaysia's <em>The Star</em> newspaper.</li><li>Concerns that the newly-elected government could close down Lynas&rsquo; plant sent shares plummeting 27% last month.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3395454\" data-linked=\"Lynas +10% after head of Malaysia review sounds more conciliatory\" data-tweet=\"$LYSCF - Lynas +10% after head of Malaysia review sounds more conciliatory https://seekingalpha.com/news/3395454-lynasplus-10-after-head-of-malaysia-review-sounds-conciliatory?source=tweet\" data-url=\"https://seekingalpha.com/news/3395454-lynasplus-10-after-head-of-malaysia-review-sounds-conciliatory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395453\" data-ts=\"1538745078\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSGX\" target=\"_blank\">HSGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395453-premarket-losers-of-9-05-10-5-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (10/5/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/HSGX' title='Histogenics Corporation'>HSGX</a>&nbsp;<font color='red'>-43%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3395438-histogenics-41-percent-pricing-public-offering-common-stock-warrants\" target=\"_blank\">pricing</a> public offering of common stock and warrants.</li><li><a href='https://seekingalpha.com/symbol/KMPH' title='KemPharm'>KMPH</a>&nbsp;<font color='red'>-33%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3395279-kempharm-launches-stock-offering\" target=\"_blank\">announcing</a> common stock offering.</li><li><a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a> <font color='red'>-30%</font>.</li><li><a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-23%</font>.</li><li><a href='https://seekingalpha.com/symbol/XNCR' title='Xencor, Inc.'>XNCR</a>&nbsp;<font color='red'>-16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3395430-xencor-announces-mid-stage-lupus-data-xmab-5871-shares-7-percent-premarket\" target=\"_blank\">announcing</a> mid-stage Lupus data on XmAb 5871.</li><li><a href='https://seekingalpha.com/symbol/AZRE' title='Azure Power'>AZRE</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3395395-azure-power-prices-14_8m-equity-offering\" target=\"_blank\">pricing</a> 14.8M equity offering.</li><li><a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395453\" data-linked=\"Premarket Losers as of 9:05 am (10/5/2018)\" data-tweet=\"$HSGX $OCGN $KMPH - Premarket Losers as of 9:05 am (10/5/2018) https://seekingalpha.com/news/3395453-premarket-losers-of-9-05-10-5-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3395453-premarket-losers-of-9-05-10-5-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395451\" data-ts=\"1538744730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEP\" target=\"_blank\">PEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395451-macquarie-warns-on-flat-margins-pepsico\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macquarie warns on flat margins at PepsiCo</a></h4><ul> <li>PepsiCo (NYSE:<a href='https://seekingalpha.com/symbol/PEP' title='PepsiCo Inc.'>PEP</a>) is on watch after Macquarie <a href=\"https://www.marketwatch.com/story/pepsico-stock-falls-to-extend-weekly-slide-after-analyst-downgrade-2018-10-05?mod=newsviewer_click\" target=\"_blank\">lowers</a> the beverage stock to a Neutral rating from Outperform on growth concerns.</li> <li>\"Organic sales growth will require more investment,\" writes analyst Caroline Levy. \"We believe these pressures will remain a drag on margins,\" she notes.</li> <li>Levy and team expect flat margins out of PepsiCo in 2019. The price target on PepsiCo is dropped to $107.</li> <li>Shares of PepsiCo are <font color='red'>down 1%</font> in premarket trading to $105.85. On a YTD look, PepsiCo is 11.1% lower.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3395451\" data-linked=\"Macquarie warns on flat margins at PepsiCo\" data-tweet=\"$PEP - Macquarie warns on flat margins at PepsiCo https://seekingalpha.com/news/3395451-macquarie-warns-on-flat-margins-pepsico?source=tweet\" data-url=\"https://seekingalpha.com/news/3395451-macquarie-warns-on-flat-margins-pepsico\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395449\" data-ts=\"1538744544\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOLD\" target=\"_blank\">BOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395449-audentes-therapeutics-to-provide-update-on-interim-data-from-aspiro-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Audentes Therapeutics to provide update on interim data from ASPIRO trial</a></h4><ul> <li>Audentes Therapeutics&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a>) will <a href=\"https://seekingalpha.com/pr/17292233-audentes-therapeutics-provide-update-new-positive-interim-data-aspiro-phase-1-2-clinical\" target=\"_blank\">present</a> new positive interim data from ASPIRO, the Phase 1/2 clinical trial of AT132 for the treatment of X-linked Myotubular Myopathy &#40;XLMTM&#41; at the 23rd International Annual Congress of the World Muscle Society, on October 5.</li>  <li>The newly reported data include follow-up assessments ranging from 4 to 48 weeks for the eight patients enrolled in ASPIRO to date.</li><li>Key assessments include neuromuscular function as measured by CHOP INTEND; respiratory function as measured by maximal inspiratory pressure and ventilator dependence; and vector transduction, transgene expression and histological improvement as assessed via muscle biopsy.</li><li>All treated patients continue to show meaningful improvements, with no new treatment-related SAEs.</li><li>Shares are down&nbsp;<font color='red'>4%</font>&nbsp;premarket.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3395449\" data-linked=\"Audentes Therapeutics to provide update on interim data from ASPIRO trial\" data-tweet=\"$BOLD - Audentes Therapeutics to provide update on interim data from ASPIRO trial https://seekingalpha.com/news/3395449-audentes-therapeutics-to-provide-update-on-interim-data-from-aspiro-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3395449-audentes-therapeutics-to-provide-update-on-interim-data-from-aspiro-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395446\" data-ts=\"1538743989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNVGY\" target=\"_blank\">LNVGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395446-lenovo-denies-super-micro-ties-after-share-slide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lenovo denies Super Micro ties after share slide</a></h4><ul><li>        Lenovo (<a href='https://seekingalpha.com/symbol/LNVGY' title='Lenovo Group Ltd. ADR'>OTCPK:LNVGY</a>)&nbsp;<font color='red'>dropped over 15%</font>&nbsp;in Asian trading on yesterday&rsquo;s Bloomberg Businessweek report that China was using Super Micro products to hide chips meant to spy on U.S. companies.</li><li>               Lenovo <a href=\"https://www.cnbc.com/2018/10/05/lenovo-tumbles-after-report-about-alleged-chinese-spy-chips.html\" target=\"_blank\">tells CNBC</a> that Super Micro &ldquo;is not a supplier to Lenovo in any capacity. Furthermore, as a global company we take extensive steps to protect the ongoing integrity of our supply chain.&rdquo;&nbsp;</li><li>               Lenovo&rsquo;s share slide was likely due to geography since the company is headquartered in Hong Kong with centers in mainland China.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395052-amazon-apple-refute-bloomberg-report-chinese-supply-chain-attack\" target=\"_blank\">Amazon, Apple refute Bloomberg report on Chinese supply chain attack</a> (Oct. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395181-super-micro-minus-54_5-percent-supply-chain-sabotage-report\" target=\"_blank\">Super Micro -54.5% on supply chain sabotage report</a> (Oct. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395249-super-micro-strongly-refutes-bloomberg-report\" target=\"_blank\">Super Micro \"strongly refutes\" Bloomberg report</a> (Oct. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395305-apple-denies-businessweek-story-says-gag-order\" target=\"_blank\">Apple again denies Businessweek story, says there's no gag order</a> (Oct. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395446\" data-linked=\"Lenovo denies Super Micro ties after share slide\" data-tweet=\"$LNVGY - Lenovo denies Super Micro ties after share slide https://seekingalpha.com/news/3395446-lenovo-denies-super-micro-ties-after-share-slide?source=tweet\" data-url=\"https://seekingalpha.com/news/3395446-lenovo-denies-super-micro-ties-after-share-slide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395443\" data-ts=\"1538743735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRA\" target=\"_blank\">NTRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395443-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Natera (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRA' title='Natera'>NTRA</a>) initiated with Neutral rating and $26 (11% upside) price target at JPMorgan.</li><li>Evolent Health (NYSE:<a href='https://seekingalpha.com/symbol/EVH' title='Evolent Health'>EVH</a>) resumed with Outperform rating and $35 (33% upside) price target at Leerink Partners.</li><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) upgraded to Outperform at BMO Capital Markets after releasing positive data on diabetes candidates yesterday.</li><li>Adamas Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a>) downgraded to Neutral at BofA/Merrill Lynch citing a survey of doctors that revealed dropouts are occurring with GOCOVRI due to the high cost and difficulty for patients in securing prior authorizations. Shares are down a fraction premarket.</li><li>Mylan N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>) downgraded to Neutral with a $37 (3% upside) price target at Mizuho citing softer expectations for biosimilars. Shares down&nbsp;<font color='red'>1%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395443\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$NTRA $NTRA $EVH - Premarket analyst action - healthcare https://seekingalpha.com/news/3395443-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3395443-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395439\" data-ts=\"1538743541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395439-guts-of-jobs-report-better-headline-yields-shoot-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guts of jobs report better than headline; yields shoot higher</a></h4><ul><li>The headlines say big miss - with just 134K jobs added vs. 185K expected. Some economists, however, were predicting a messy/soft number thanks to the hurricane that hit the southeast. Also, there were revisions, with July's 147K gain revised higher by 18K jobs, and August's 201K gain revised higher by a full 69K.</li><li>Then there's the unemployment rate, which fell all the way to 3.7% from 3.9%, and against expectations for 3.8%. The labor force participation rate was steady at 62.7%.</li><li>Taking all this together, the report is looking closer to a beat than a miss.</li><li>Average hourly earnings were up $0.08 to $27.24, and higher by 2.8% Y/Y (inline with estimates). The average workweek was flat at 34.5 hours.</li><li><a href=\"https://stats.bls.gov/news.release/empsit.htm\" target=\"_blank\">Full report</a></li><li>Yields continue to move higher, with the 10-year Treasury jumping more than four basis points since the number hit, now up to 3.23%. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='red'>-0.6%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='green'>+1.2%</font></li><li>The dollar (<a href='https://seekingalpha.com/symbol/UUP' title='Invesco DB USD Bull ETF'>UUP</a>, <a href='https://seekingalpha.com/symbol/UDN' title='Invesco DB USD Bear ETF'>UDN</a>) knee-jerked lower on the 134K headline, but is now modestly in the green. Gold (NYSEARCA:<a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>) has added a couple of dollars as well.</li><li>Stock index futures (<a href='https://seekingalpha.com/symbol/SPY' title='SPDR S&P 500 Trust ETF'>SPY</a>, <a href='https://seekingalpha.com/symbol/QQQ' title='Invesco QQQ ETF'>QQQ</a>, <a href='https://seekingalpha.com/symbol/DIA' title='SPDR Dow Jones Industrial Average ETF'>DIA</a>) continue with slight gains.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395427-september-payroll-miss-134k-jobs-added-ue-rate-slips-3_7-percent\" target=\"_blank\">September payroll miss with 134K jobs added; UE rate slips to 3.7%</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395439\" data-linked=\"Guts of jobs report better than headline; yields shoot higher\" data-tweet=\"$TLT $TBT $UUP - Guts of jobs report better than headline; yields shoot higher https://seekingalpha.com/news/3395439-guts-of-jobs-report-better-headline-yields-shoot-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3395439-guts-of-jobs-report-better-headline-yields-shoot-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>120&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395438\" data-ts=\"1538743422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSGX\" target=\"_blank\">HSGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395438-histogenics-down-41-on-pricing-public-offering-of-common-stock-and-warrants\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Histogenics down 41% on pricing public offering of common stock and warrants</a></h4><ul> <li>Histogenics (NASDAQ:<a href='https://seekingalpha.com/symbol/HSGX' title='Histogenics Corporation'>HSGX</a>) <a href=\"https://seekingalpha.com/pr/17292242-histogenics-corporation-announces-pricing-public-offering-common-stock-warrants\" target=\"_blank\">prices</a> its public offering of 26,155,000 shares of common stock and warrants to purchase up to 19,616,250 common shares, at a combined price of $0.65 per share.</li><li>The expected gross proceeds are $17M. The warrants are exercisable at a price of $0.70 per share of common stock and have a term of five years from the date of issuance.</li>   <li>Net proceeds will be used to complete the BLA submission and commercialization of NeoCart, and for general corporate purposes.</li><li>Closing date is October 10.</li><li>Shares are down&nbsp;<font color='red'>41%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395265-histogenics-readies-stock-offering-shares-23-percent-hours\" target=\"_blank\">Histogenics readies stock offering; shares down 23% after hours</a> (Oct. 4)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3395438\" data-linked=\"Histogenics down 41% on pricing public offering of common stock and warrants\" data-tweet=\"$HSGX $OCGN - Histogenics down 41% on pricing public offering of common stock and warrants https://seekingalpha.com/news/3395438-histogenics-down-41-on-pricing-public-offering-of-common-stock-and-warrants?source=tweet\" data-url=\"https://seekingalpha.com/news/3395438-histogenics-down-41-on-pricing-public-offering-of-common-stock-and-warrants\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395435\" data-ts=\"1538743227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTXI\" target=\"_blank\">GTXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395435-gtx-up-51-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gtx up 51% premarket</a></h4><ul><li>Nano cap GTx (NASDAQ:<a href='https://seekingalpha.com/symbol/GTXI' title='GTx, Inc.'>GTXI</a>) is up&nbsp;<font color='green'>51%</font>&nbsp;premarket on robust volume on no readily available news.</li><li>Shares cratered a couple of weeks ago after it announced unsuccessful results in a clinical trial evaluating enobosarm in postmenopausal women with stress urinary incontinence.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392097-gtxs-enobosarm-flunks-late-stage-study-women-sui-shares-91-percent-premarket\" target=\"_blank\">GTx's enobosarm flunks late-stage study in women with SUI; shares down 91% premarket</a> (Sept. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395435\" data-linked=\"Gtx up 51% premarket\" data-tweet=\"$GTXI $ONCT - Gtx up 51% premarket https://seekingalpha.com/news/3395435-gtx-up-51-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3395435-gtx-up-51-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395433\" data-ts=\"1538742937\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPX\" target=\"_blank\">TPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395433-official-mattress-firm-files-for-bankruptcy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">It&#39;s official: Mattress Firm files for bankruptcy</a></h4><ul> <li>Mattress Firm officially filed for bankruptcy as expected, according to CNBC.</li> <li>The Chapter 11 filing includes a notice that about 200 stores will close within a few days. The precise store liquidation plan of Mattress Firm could have implications for a number of retailers - including Tempur Sealy International (NYSE:<a href='https://seekingalpha.com/symbol/TPX' title='Tempur Sealy International Inc.'>TPX</a>), Sleep Number (NASDAQ:<a href='https://seekingalpha.com/symbol/SNBR' title='Sleep Number Corporation'>SNBR</a>), Hooker Furniture (NASDAQ:<a href='https://seekingalpha.com/symbol/HOFT' title='Hooker Furniture Corporation'>HOFT</a>), Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>) via the Casper business and La-Z-Boy (NYSE:<a href='https://seekingalpha.com/symbol/LZB' title='La-Z-Boy Incorporated'>LZB</a>).</li><li>Mattress Firm operates over 3K stores in the U.S., which could put a little bit of pressure on certain strip mall operators depending upon how many stores end up being boarded up.</li><li>Shares of Tempur Sealy are already <font color='green'>up 5.81%</font> in premarket action following the bankruptcy update.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3395433\" data-linked=\"It&#39;s official: Mattress Firm files for bankruptcy\" data-tweet=\"$TPX $TPX $SNBR - It&#39;s official: Mattress Firm files for bankruptcy https://seekingalpha.com/news/3395433-official-mattress-firm-files-for-bankruptcy?source=tweet\" data-url=\"https://seekingalpha.com/news/3395433-official-mattress-firm-files-for-bankruptcy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395429\" data-ts=\"1538742676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIMO\" target=\"_blank\">SIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395429-silicon-motionminus-3_6-on-preliminary-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silicon Motion -3.6% on preliminary Q3 results</a></h4><ul><li>        Silicon Motion (NASDAQ:<a href='https://seekingalpha.com/symbol/SIMO' title='Silicon Motion Technology Corporation'>SIMO</a>)&nbsp;<a href=\"https://seekingalpha.com/pr/17292237-silicon-motion-announces-preliminary-third-quarter-2018-revenue-earnings-conference-call\" target=\"_blank\">announces</a> preliminary Q3 results with revenue expected in the lower half of the guidance range of $136M to $142.9M.</li><li>                  Non-GAAP gross margin is expected at the higher end of the guided 48.5% to 50.5%.    </li><li>               Silicon Motion will release Q3 results after the market closes on October 30. &nbsp;&nbsp;</li><li>               SIMO shares are&nbsp;<font color='red'>down 3.6%</font>&nbsp;premarket to $50.01.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3395429\" data-linked=\"Silicon Motion -3.6% on preliminary Q3 results\" data-tweet=\"$SIMO - Silicon Motion -3.6% on preliminary Q3 results https://seekingalpha.com/news/3395429-silicon-motionminus-3_6-on-preliminary-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3395429-silicon-motionminus-3_6-on-preliminary-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395430\" data-ts=\"1538742676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XNCR\" target=\"_blank\">XNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395430-xencor-announces-mid-stage-lupus-data-on-xmab-5871-shares-down-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xencor announces mid-stage Lupus data on XmAb 5871; shares down 7% premarket</a></h4><ul><li>Thinly traded Xencor (NASDAQ:<a href='https://seekingalpha.com/symbol/XNCR' title='Xencor, Inc.'>XNCR</a>) slips<font color='red'> 7%</font>&nbsp;premarket following its <a href=\"https://seekingalpha.com/pr/17292232-xencor-announces-topline-results-phase-2-study-xmab-5871-systemic-lupus-erythematosus\" target=\"_blank\">announcement </a>of topline results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02725515?intr=xmab+5871&amp;lead=xencor&amp;phase=1&amp;rank=2\" target=\"_blank\">Phase 2 clinical trial</a> evaluating XmAb 5871 in patients with systemic lupus erythematosus &#40;SLE&#41;. The data will be presented at the American College of Rheumatology &#40;ACR&#41; Annual Meeting in Chicago on October 23.</li><li>The primary endpoint was the proportion of patients with no loss of improvement &#40;LOI&#41;. Improvement was maintained in 42% (n=21/50) of patients in the treatment arm compared to 28.6% (n=12/42) for placebo, but the separation was not statistically significant (p=0.18). The company says the higher placebo response rate was due to the withdrawal of patients from both arms for reasons other than LOI or adverse events.</li><li>In the efficacy-evaluable population, patients in the treatment group experienced a statistically significant longer time to LOI (median = 230 days) versus control (median = 131 days) (p=0.025).</li><li>No new safety signals were observed.</li><li><a href=\"http://www.xencor.com/pipeline/xmab-5871/\" target=\"_blank\">XmAb5871&nbsp;</a>is a monoclonal antibody that targets CD19, specifically TcyRIIb, a receptor that inhibits B cell function without killing the cells. Inhibiting the function of B cells is a proven approach to treating many autoimmune diseases.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395430\" data-linked=\"Xencor announces mid-stage Lupus data on XmAb 5871; shares down 7% premarket\" data-tweet=\"$XNCR - Xencor announces mid-stage Lupus data on XmAb 5871; shares down 7% premarket https://seekingalpha.com/news/3395430-xencor-announces-mid-stage-lupus-data-on-xmab-5871-shares-down-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3395430-xencor-announces-mid-stage-lupus-data-on-xmab-5871-shares-down-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395421\" data-ts=\"1538742180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395421-new-age-beveragesplus-5-national-cbd-roll-out-in-works\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages +5% with national CBD roll-out in the works</a></h4><ul><li>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) is planning for a large-scale roll of its cannabis-based drink product next March or April.</li><li>New Age CEO Brent Willis said at the B. Riley FBR Consumer &amp; Media Conference yesterday that the company is already <a href=\"https://www.bloomberg.com/news/articles/2018-10-04/new-age-beverages-is-in-talks-with-retailers-for-cbd-pre-orders\" target=\"_blank\">talking</a> to retailers in states where the cannabis drink would be legal. Willis sees New Age positioned to be the first to execute CBD beverages on a national scale if legalization sweeps across the U.S.</li><li>Shares of NBEV are <font color='green'>up 5.15%</font> in premarkety trading to follow on yesterday's 5.42% jump.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395421\" data-linked=\"New Age Beverages +5% with national CBD roll-out in the works\" data-tweet=\"$NBEV - New Age Beverages +5% with national CBD roll-out in the works https://seekingalpha.com/news/3395421-new-age-beveragesplus-5-national-cbd-roll-out-in-works?source=tweet\" data-url=\"https://seekingalpha.com/news/3395421-new-age-beveragesplus-5-national-cbd-roll-out-in-works\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395413\" data-ts=\"1538741166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BJRI\" target=\"_blank\">BJRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395413-bjs-restaurantsplus-2-after-piper-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BJ&#39;s Restaurants +2% after Piper upgrade</a></h4><ul> <li>Piper Jaffray lifts BJ's Restaurants (NASDAQ:<a href='https://seekingalpha.com/symbol/BJRI' title='BJ&#39;s Restaurants, Inc.'>BJRI</a>) to an Overweight rating after having the restaurant/microbrewer operator set at Neutral.</li> <li>The firm's price target of $76 on BJRI reps 15% upside potential.</li> <li>Shares of BJ's are <font color='green'>up 2.01%</font> in premarket trading to $67.60 vs. a 52-week trading range of $29.40 to $76.50.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3395413\" data-linked=\"BJ&#39;s Restaurants +2% after Piper upgrade\" data-tweet=\"$BJRI - BJ&#39;s Restaurants +2% after Piper upgrade https://seekingalpha.com/news/3395413-bjs-restaurantsplus-2-after-piper-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3395413-bjs-restaurantsplus-2-after-piper-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395411\" data-ts=\"1538740880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPGP\" target=\"_blank\">IPGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395411-ig-photonics-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IG Photonics shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in IG Photonics (NASDAQ:<a href='https://seekingalpha.com/symbol/IPGP' title='IPG Photonics Corporation'>IPGP</a>) pending the release of news.</li><li><strong>Update</strong>: The company has <a href=\"https://www.sec.gov/Archives/edgar/data/1111928/000111192818000121/exhibit991-2018930prerelea.htm\" target=\"_blank\">lowered </a>its Q3 non-GAAP EPS guidance to $1.83 - 1.87 from $1.80 - 2.05 and its revenue guidance to $355M - 360M from $360M - 390M due to foreign currency headwinds.</li><li>Shares will resume trading at 8:30 am ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395411\" data-linked=\"IG Photonics shares halted pending news\" data-tweet=\"$IPGP - IG Photonics shares halted pending news https://seekingalpha.com/news/3395411-ig-photonics-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3395411-ig-photonics-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395407\" data-ts=\"1538740695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGNX\" target=\"_blank\">PGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395407-progenics-pet-imaging-agent-for-prostate-cancer-shows-positive-action-in-phase-2-3-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progenics&#39; PET imaging agent for prostate cancer shows positive action in Phase 2/3 study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17292146-progenics-reports-results-phase-2-3-trial-psma-pet-imaging-agent-pyl-detection-prostate\" target=\"_blank\">Results </a>from a Phase 2/3 study, OSPREY 2301, evaluating Progenics Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/PGNX' title='Progenics Pharmaceuticals Inc.'>PGNX</a>) PET imaging agent PyL (18F-DCFPyL) for visualizing prostate cancer demonstrated its utility in detecting distant metastatic prostate cancer lesions as well as the absence of pelvic lymph node disease.</li><li>In patients with metastatic or recurrent prostate cancer, PyL showed sensitivity (correctly identifying true positives) of 93 - 99% with a positive predictive value (the proportion of positives that are true positives) of 81 - 88% (in other words, there were some false positives).</li><li>PyL's specificity (correctly identifying true negatives) in confirming the absence of pelvic lymph node disease was 96 - 99% with a negative predictive value of 81 - 84% (there were some false negatives).</li><li>On the safety front, PyL was well-tolerated. 7% of participants experienced at least one treatment-related adverse event. The most common were dysgeusia (distortion of sense of taste) (2.1%) and headache (2.1%).</li><li>Complete data will be submitted for presentation at a future medical conference.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li><li>Shares will resume trading at 8:00 am ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395407\" data-linked=\"Progenics&#39; PET imaging agent for prostate cancer shows positive action in Phase 2/3 study\" data-tweet=\"$PGNX - Progenics&#39; PET imaging agent for prostate cancer shows positive action in Phase 2/3 study https://seekingalpha.com/news/3395407-progenics-pet-imaging-agent-for-prostate-cancer-shows-positive-action-in-phase-2-3-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3395407-progenics-pet-imaging-agent-for-prostate-cancer-shows-positive-action-in-phase-2-3-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395397\" data-ts=\"1538739421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGNX\" target=\"_blank\">PGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395397-progenics-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progenics shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Progenics Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PGNX' title='Progenics Pharmaceuticals Inc.'>PGNX</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395397\" data-linked=\"Progenics shares halted pending news\" data-tweet=\"$PGNX - Progenics shares halted pending news https://seekingalpha.com/news/3395397-progenics-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3395397-progenics-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395396\" data-ts=\"1538739316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLX\" target=\"_blank\">PLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395396-protalix-up-4-premarket-on-additional-data-on-fabry-candidate-prxminus-102\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Protalix up 4% premarket on additional data on Fabry candidate PRX-102</a></h4><ul><li>Protalix BioTherapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLX' title='Protalix BioTherapeutics, Inc'>PLX</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on modest volume following its <a href=\"https://seekingalpha.com/pr/17292122-protalix-biotherapeutics-presents-positive-preliminary-data-bridge-study-pegunigalsidase-alfa\" target=\"_blank\">announcement </a>of additional data from the open-label BRIDGE study evaluating PRX-102 (pegunigalsidase alfa) in Fabry patients previously receiving Shire's (NASDAQ:<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>) Replagal (agalsidase alfa). The results are being presented today at the 1st Canadian Symposium on Lysosomal Diseases in Sherbrooke, Quebec.</li><li>An in vitro analysis showed that PRX-102 delivered significantly longer enzyme activity than both commercially available enzyme replacement therapies (ERTs). Specifically, ~84% of PRX-102's activity was preserved after 10 days compared to ~1% for the other ERTs.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392180-protalix-20-percent-positive-prxminus-102-data-fabry\" target=\"_blank\">Protalix up 20% on positive PRX-102 data in Fabry</a> (Sept. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395396\" data-linked=\"Protalix up 4% premarket on additional data on Fabry candidate PRX-102\" data-tweet=\"$PLX $PLX $SHPG - Protalix up 4% premarket on additional data on Fabry candidate PRX-102 https://seekingalpha.com/news/3395396-protalix-up-4-premarket-on-additional-data-on-fabry-candidate-prxminus-102?source=tweet\" data-url=\"https://seekingalpha.com/news/3395396-protalix-up-4-premarket-on-additional-data-on-fabry-candidate-prxminus-102\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395392\" data-ts=\"1538738851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPQ\" target=\"_blank\">HPQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395392-jpmorgan-downgrades-hp-on-limited-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan downgrades HP on limited upside</a></h4><ul><li>        JPMorgan downgrades HP (NYSE:<a href='https://seekingalpha.com/symbol/HPQ' title='HP Inc.'>HPQ</a>) from Overweight to Neutral but increases the target by a dollar to $29, a nearly 10% upside to yesterday&rsquo;s close.</li><li>               The firm comes away from HP&rsquo;s analyst day seeing limited catalysts that could generate upside.&nbsp;</li><li>               Source: StreetAccount. &nbsp;&nbsp;&nbsp;</li><li>               HPQ shares are&nbsp;<font color='red'>down 1.1%&nbsp;</font>premarket to $26.14.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395057-maxim-raises-hp-target-analyst-day\" target=\"_blank\">Maxim raises its HP target after analyst day</a> (Oct. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395392\" data-linked=\"JPMorgan downgrades HP on limited upside\" data-tweet=\"$HPQ - JPMorgan downgrades HP on limited upside https://seekingalpha.com/news/3395392-jpmorgan-downgrades-hp-on-limited-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3395392-jpmorgan-downgrades-hp-on-limited-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395388\" data-ts=\"1538738391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395388-himaxplus-5_8-on-upside-preliminary-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Himax +5.8% on upside preliminary Q3 results</a></h4><ul><li>        Himax (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>)&nbsp;<font color='green'>gains 5.8%</font>&nbsp;premarket after <a href=\"https://seekingalpha.com/pr/17292070-himax-pre-announces-key-financial-results-third-quarter-2018-revenue-gross-margin-eps\" target=\"_blank\">pre-announcing</a> key Q3 results including $188.4M in revenue (+4% Q/Q; consensus: $182.93M), gross margin of 23.4% (guidance: 22.5%), and earnings per diluted ADS of $0.026 (guidance: $0.015; consensus: $0.01). &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3395388\" data-linked=\"Himax +5.8% on upside preliminary Q3 results\" data-tweet=\"$HIMX - Himax +5.8% on upside preliminary Q3 results https://seekingalpha.com/news/3395388-himaxplus-5_8-on-upside-preliminary-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3395388-himaxplus-5_8-on-upside-preliminary-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395384\" data-ts=\"1538737956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRO\" target=\"_blank\">GPRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395384-goproplus-7_8-on-strong-hero7-black-week-one-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoPro +7.8% on strong HERO7 Black week-one sales</a></h4><ul><li>GoPro (NASDAQ:<a href='https://seekingalpha.com/symbol/GPRO' title='GoPro'>GPRO</a>)&nbsp;<font color='green'>gains 7.8%</font>&nbsp;premarket to $6.75 after <a href=\"https://seekingalpha.com/pr/17292009-gopro-hero7-black-achieves-strongest-week-one-unit-sell-thru-company-history\" target=\"_blank\">announcing</a> that the HERO7 Black has achieved the highest week-one retail unit sell-thru of any new camera in the company&rsquo;s history. Unit numbers weren&rsquo;t disclosed.</li><li>The company also refutes a social media claim that a major U.S. retailer had recalled the HERO7 line.</li></ul><div class=\"tiny-share-widget\" data-id=\"3395384\" data-linked=\"GoPro +7.8% on strong HERO7 Black week-one sales\" data-tweet=\"$GPRO - GoPro +7.8% on strong HERO7 Black week-one sales https://seekingalpha.com/news/3395384-goproplus-7_8-on-strong-hero7-black-week-one-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3395384-goproplus-7_8-on-strong-hero7-black-week-one-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3395350\" data-ts=\"1538721788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3395350-chinese-spy-chip-report-weighs-on-apple-suppliers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chinese spy chip report weighs on Apple suppliers</a></h4><ul><li>Shares in Apple's (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) suppliers saw a broad decline overnighton the back of a bombshell report that alleged Chinese spy chips were discovered in data center equipment used by Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) and Apple.</li><li>The tech giants have denied the allegations by Bloomberg Businessweek, which said the hack reached almost 30 U.S. companies and compromised America's technology supply chain.</li><li>Across Asia: AMS <font color='red'>-3.7%</font>, Catcher <font color='red'>-1.4%</font>, Largan <font color='red'>-7.3%</font>, LG Display <font color='red'>-2.1%</font>, Murata <font color='red'>-3.9%</font>, Wistron <font color='red'>-4.4%</font>, Hon Hai <font color='red'>-1.4%</font>, AAC Tech <font color='red'>-2.1%</font>, Merry <font color='red'>-6.6%</font>, TDK <font color='red'>-4.8%</font> TSMC <font color='red'>-1.6%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395305-apple-denies-businessweek-story-says-gag-order\" target=\"_blank\">Apple again denies Businessweek story, says there's no gag order</a> (Oct. 04 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3395350\" data-linked=\"Chinese spy chip report weighs on Apple suppliers\" data-tweet=\"$AAPL $AAPL $AMZN - Chinese spy chip report weighs on Apple suppliers https://seekingalpha.com/news/3395350-chinese-spy-chip-report-weighs-on-apple-suppliers?source=tweet\" data-url=\"https://seekingalpha.com/news/3395350-chinese-spy-chip-report-weighs-on-apple-suppliers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>97&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":63,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}